Serum lipoprotein(a) level and clinical coronary stenosis progression in patients with myocardial infarction: Re-revascularization rate is high in patients with high-Lp(a)

Circulation Journal

Volumn 70, Issue 2, 2006, Pages 156-162

  Morita, Yukiko ^a   Himeno, Hideo ^a   Yakuwa, Hideyuki ^a   Usui, Takashi ^a  

^a Fujisawa City Hospital   (Japan)

Author keywords

Acute myocardial infarction; Coronary stenosis; Lipoprotein(a)

Indexed keywords

LIPOPROTEIN A;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DISEASE COURSE; FEMALE; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERLIPOPROTEINEMIA; HYPOLIPOPROTEINEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PATIENT CODING; PERCUTANEOUS CORONARY INTERVENTION; RESTENOSIS; RISK FACTOR;

ADULT; AGED; CORONARY RESTENOSIS; FEMALE; HUMANS; LIPOPROTEIN(A); MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NEOVASCULARIZATION, PATHOLOGIC; PREDICTIVE VALUE OF TESTS; RISK FACTORS;

EID: 31644435758     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.70.156     Document Type: Article

References (46)

1. Dahlen GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 1986; 74: 758-765.
2. Orth-Gomér K, Mittleman MA, Schenck-Gustafsson K, Wamala SP, Eriksson M, Belkic K, et al. Lipoprotein(a) as a determinant of coronary heart disease in young women. Circulation 1997; 95: 329-334.
3. Koltringer P, Jurgens G. A dominant role of lipoprotein(a) in an investigation and evaluation of parameters indicating the development of cervical atherosclerosis. Atherosclerosis 1985; 58: 187-198.
4. Murai A, Miyahara T, Fujimoto N, Matsuda M, Kameyama M. Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis 1986; 59: 199-204.
5. Peltier M, Peltier MCI, Sarano ME, Lesbre JPM, Colas JL, Tribouilloy CM. Elevated serum lipoprotein(a) level is an independent marker of severity of thoracic aortic atherosclerosis. Chest 2002; 121: 1589-1594.
6. Berg K. A new serum type system in man: The Lp system. Acta Pathol Microbiol Scand 1963; 59: 369-382.
7. Hearn JA, Donohue BC, Ba'albaki H, Douglas JS, King SB III, Lembo NJ, et al. Usefulness of serum lipoprotein(a) as a predictor of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1992; 69: 736-739.
8. Miyata M, Biro S, Arima S, Hamasaki S, Kaieda H, Nakao S, et al. High serum concentration of lipoprotein(a) is a risk factor for restenosis after percutaneous transluminal coronary angioplasty in Japanese patients with single-vessel disease. Am Heart J 1996; 132: 269-273.
9. Desmarais RL, Sarembock IJ, Ayers CR, Velmon SM, Powers ER, Gimple LW. Elevated serum lipoprotein(a) is a risk factor for clinical recurrence after coronary balloon angioplasty. Circulation 1995; 91: 1403-1409.
10. Yamamoto H, Imazu M, Yamabe T, Ueda H, Hattori Y, Yamakido M. Risk factors for restenosis after percutaneous transluminal coronary angioplasty: Role of lipoprotein(a). Am Heart J 1995; 130: 1168-1173.
11. Tenda K, Saikawa T, Maeda T, Sato Y, Niwa H, Inoue Y. The relationship between serum lipoprotein(a) and restenosis after initial elective percutaneous transluminal coronary angioplasty. Jpn Circ J 1993; 57: 789-795.
12. Hoff HF, Beck GJ, Skibinski CI, Jürgens G, O'Neil J, Kramer J, et al. Serum Lp(a) level as a predictor of vein graft stenosis after coronary artery bypass surgery in patients. Circulation 1988; 77: 1238-1244.
13. Ribichini F, Steffenino G, Dellavalle A, Vado A, Ferrero V, Camilla T, et al. Plasma lipoprotein(a) is not a predictor for restenosis after elective high-pressure coronary stenting. Circulation 1998; 98: 1172-1177.
14. Wehinger A, Kastrati A, Elezi S, Baum H, Braun S, Neumann FJ, et al. Lipoprotein(a) and coronary thrombosis and restenosis after stent placement. J Am Coll Cardiol 1999; 33: 1005-1012.
15. Gazzaruso C, Garzaniti A, Falcone C, Geroldi D, Turpini C, Frantino P. Restenosis after intracoronary stent placement: Can apolipoprotein(a) polymorphism play a role? Int J Cardiol 2003; 87: 91-98.
16. Gazzaruso C, Garzaniti A, Falcone C, Puija A, Geroldi D, Giordanetti S, et al. Lipoprotein(a), apolipoprotein(a) polymorphism and restenosis after intracoronary stent placement in type 2 diabetic patients. J Diabetes Complications 2003; 17: 135-140.
17. Berg K. Lp(a) lipoprotein: An overview. Chem Phys Lipids 1994; 67-68: 9-16.
18. Hilden J, Glasziou P. Regret graphs, diagnostic uncertainty and Youden's Index. Stat Med 1996; 15: 969-986.
19. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: A fundamental evaluation tool in clinical medicine. Clin Chem 1993; 39: 561-577.
20. Daida H, Lee YJ, Yokoi H, Kanoh T, Ishiwata S, Kato K, et al. Prevention of restenosis after percutaneous transluminal coronary angioplasty by reducing lipoprotein(a) levels with low-density lipoprotein apheresis. Am J Cardiol 1994; 73: 1037-1040.
21. Eaton DL, Fless GM, Kohr WJ, McLean JW, Xu QT, Miller CG, et al. Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen. Proc Natl Acad Sci USA 1987; 84: 3224-3228.
22. McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987; 330: 132-137.
23. Cantin B, Gagnon F, Moorjani S, Després JP, Lamarche B, Lupien PJ, et al. Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study. J Am Coll Cardiol 1998; 31: 519-525.
24. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 1993; 270: 2195-2199.
25. Kinlay S, Dobson AJ, Heller RF, McElduff P, Alexander H, Dickeson J. Risk of primary and recurrent acute myocardial infarction from lipoprotein(a) in men and women. J Am Coll Cardiol 1996; 28: 870-875.
26. Jauhiainen M, Koskinen P, Ehnholm C, Frick MH, Manttari M, Manninen V, et al. Lipoprotein(a) and coronary heart disease risk: A nested case - control study of the Helsinki Heart Study participants. Atherosclerosis 1991; 89: 59-67.
27. Igarashi Y, Aizawa Y, Satoh T, Konno T, Ojima K, Aizawa Y. Predictors of adverse long-term outcome in acute myocardial infarction patients undergoing primary percutaneous transluminal coronary angioplasty: With special reference to the admission concentration of lipoprotein(a). Circ J 2003; 67: 605-611.
28. Utermann G. The mysteries of lipoprotein(a). Science 1989; 246: 904-910.
29. Terres W, Tatsis E, Pfalzer B, Beil U, Beisiegel U, Hamm CW. Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein (a). Circulation 1995; 91: 948-950.
30. Tamura A, Watanabe T, Mikuriya Y, Nasu M. Serum lipoprotein(a) concentrations are related to coronary disease progression without new myocardial infarction. Br Heart J 1995; 74: 365-369.
31. Cooke T, Sheahan R, Foley D, Reilly M, D'Arey G, Jauch W, et al. Lipoprotein(a) in restenosis after percutaneous transluminal coronary angioplasty and coronary artery disease. Circulation 1994; 89: 1593-1598.
32. Shah PK, Amin J. Low high density lipoprotein level is associated with increased restenosis rate after coronary angioplasty. Circulation 1992; 85: 1279-1285.
33. Zairis MN, Ambrose JA, Manousakis SJ, Stefanidis AS, Papadaki OA, Bilianou HI, et al. The impact of plasma levels of C-reactive protein, lipoprotein(a) and homocysteine on the long-term prognosis after successful coronary stenting. J Am Coll Cardiol 2002; 40: 1375-1382.
34. Maeda S, Abe A, Seishima M, Makino K, Noma A, Kawade M. Transient changes of serum lipoprotein(a) as an acute phase protein. Atherosclerosis 1989; 78: 145-150.
35. Noma A, Abe A, Maeda S, Seishima M, Makino K, Yano Y, et al. Lp(a): Acute-phase reactant? Chem Phys Lipids 1994; 67-68: 411-417.
36. Kojima S, Harpel PC, Rifkin DB. Lipoprotein(a) inhibits the generation of transforming growth factor β: An endogenous inhibitor of smooth muscle cell migration. J Cell Biol 1991; 113: 1439-1445.
37. Lawn RM, Pearle AD, Kunz LL, Rubin EM, Reckless J, Metcalfe JC, et al. Feedback mechanism of focal vascular lesion formation in transgenic apolipoprotein(a) mice. J Biol Chem 1996; 271: 31367-31371.
38. Etingin OR, Hajjar DP, Hajjor KA, Harpel PC, Nachman RL. Lipoprotein(a) regulates plasminogen activator inhibitor-1 expression in endothelial cells: A potential mechanism in thrombogenesis. J Biol Chem 1991; 266: 2459-2465.
39. Mintz GS, Popma JJ, Pichard AD, Kent KM, Satler LF, Wong SC, et al. Arterial remodeling after coronary angioplasty: A serial intravascular ultrasound study. Circulation 1996; 94: 35-43.
40. Hoffmann R, Minz GS, Dussaillant GR, Popma JJ, Pichard AD, Satler LF, et al. Patterns and mechanisms of in-stent restenosis: A serial intravascular ultrasound study. Circulation 1996; 94: 1247-1254.
41. Grainger DJ, Kirschenlohr HL, Metcalfe JC, Weissberg PL, Wade DP, Lawn RM. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science 1993; 260: 1655-1658.
42. Agewall S, Fagerberg B. Lipoprotein(a) was an independent predictor for major coronary events in treated hypertensive men. Clin Cardiol 2002; 25: 287-290.
43. Ridker PM. Evaluating novel cardiovascular risk factors: Can we better predict heart attacks? Ann Intern Med 1999; 130: 933-937.
44. Iijima R, Ikari Y, Miyazaki A, Nakajima H, Hara K. Predictors of restenosis after implantation of 2.5 mm stents in small coronary arteries. Circ J 2004; 68: 236-240.
45. Savage MP, Fischman DL, Rake R, Leon MB, Schatz RA, Penn I, et al. Efficacy of coronary stenting versus balloon angioplasty in small coronary arteries: Stent restenosis study (STRESS). J Am Coll Cardiol 1998; 31: 307-311.
46. Park SW, Lee CW, Hong MK, Kim JJ, Cho GY, Nah DY, et al. Randomized comparison of coronary stenting with optimal balloon angioplasty for treatment of lesions in small coronary arteries. Eur Heart J 2000; 21: 1785-1789.